Cancer has long been medicine’s most elusive target, but a wave of new research suggests scientists may finally be closing in ...
Cervical cancer is the fourth most common cancer for women in the world, with more than 660,000 new cases and nearly 350,000 ...
COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new ...
NASHVILLE Tenn. (WKRN) — It can take more than a decade to develop a new vaccine for children. After years of research and testing, some don’t pass the safety checks. One laboratory at Vanderbilt ...
The U.S. reportedly plans to overhaul the country’s childhood vaccine schedule. The move could set public health back decades ...
Evaxion A/S has announced the initiation of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS), a pathogen responsible for a wide range of infections globally, including severe ...